Wada, N. et al. 2024. Elevated Serum Growth Differentiation Factor 15 Levels as a Potential Biomarker of the Efficacy of Imeglimin in Individuals With Type 2 Diabetes Mellitus: An Exploratory Study. Journal of Clinical Medicine Research. 16, 10 (Oct. 2024), 503–508. DOI:https://doi.org/10.14740/jocmr6031.